TY - JOUR
T1 - C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas
T2 - An initial experience
AU - Giovacchini, Giampiero
AU - Fallanca, Federico
AU - Landoni, Claudio
AU - Gianolli, Luigi
AU - Picozzi, Piero
AU - Attuati, Luca
AU - Terreni, Mariarosa
AU - Picchio, Maria
AU - Messa, Cristina
AU - Fazio, Ferruccio
PY - 2009/1
Y1 - 2009/1
N2 - Purpose:Positron emission tomography/computed tomography (PET/CT) with C-11 choline has been used for staging, restaging, and follow-up of various tumors, whereas its role for imaging meningiomas has only been preliminarily explored. The aim of this study was to compare C-11 choline and F-18 fluorodeoxyglucose (F-18 FDG) uptake in meningiomas and relate these findings to the histopathological analysis. Methods: Two sequential three-dimensional PET/CT scans with 370 MBq (10 mCi) of C-11 choline and 370 MBq (10 mCi) of F-18 FDG were performed 2 hours apart in 7 patients with histologically confirmed meningiomas. Five patients had WHO grade I and 2 had WHO grade II meningioma. For each scan, two-dimensional regions of interest were drawn on tumor boundaries and on the contralateral side on CT images and copied to the corresponding PET images. SUVmax and tumor-to-background ratio were calculated. Results: Relative to the contralateral side, C-11 choline uptake was increased in all meningiomas, whereas F-18 FDG uptake was decreased in 6 patients and increased in 1 of the 2 patients with grade II meningiomas. In the whole group, SUVmax of C-11 choline and F-18 FDG were 3.6 ± 1.3 and 5.7 ± 1.3, respectively. The tumor-to-background ratio for C-11 choline was much higher than that for F-18 FDG (5.3 ± 0.8 vs. 0.9 ± 0.2, respectively) (P <0.001). The uptake of C-11 choline was higher in patients with grade II than in grade I meningiomas. Conclusions:These preliminary results suggest that C-11 choline may better image meningiomas in comparison with F-18 FDG. Clinical applications of C-11 choline PET/CT for grading and follow-up of meningiomas need to be assessed in further studies.
AB - Purpose:Positron emission tomography/computed tomography (PET/CT) with C-11 choline has been used for staging, restaging, and follow-up of various tumors, whereas its role for imaging meningiomas has only been preliminarily explored. The aim of this study was to compare C-11 choline and F-18 fluorodeoxyglucose (F-18 FDG) uptake in meningiomas and relate these findings to the histopathological analysis. Methods: Two sequential three-dimensional PET/CT scans with 370 MBq (10 mCi) of C-11 choline and 370 MBq (10 mCi) of F-18 FDG were performed 2 hours apart in 7 patients with histologically confirmed meningiomas. Five patients had WHO grade I and 2 had WHO grade II meningioma. For each scan, two-dimensional regions of interest were drawn on tumor boundaries and on the contralateral side on CT images and copied to the corresponding PET images. SUVmax and tumor-to-background ratio were calculated. Results: Relative to the contralateral side, C-11 choline uptake was increased in all meningiomas, whereas F-18 FDG uptake was decreased in 6 patients and increased in 1 of the 2 patients with grade II meningiomas. In the whole group, SUVmax of C-11 choline and F-18 FDG were 3.6 ± 1.3 and 5.7 ± 1.3, respectively. The tumor-to-background ratio for C-11 choline was much higher than that for F-18 FDG (5.3 ± 0.8 vs. 0.9 ± 0.2, respectively) (P <0.001). The uptake of C-11 choline was higher in patients with grade II than in grade I meningiomas. Conclusions:These preliminary results suggest that C-11 choline may better image meningiomas in comparison with F-18 FDG. Clinical applications of C-11 choline PET/CT for grading and follow-up of meningiomas need to be assessed in further studies.
KW - C-11 choline
KW - F-18 FDG
KW - Meningiomas
KW - PET/CT
UR - http://www.scopus.com/inward/record.url?scp=59649096113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59649096113&partnerID=8YFLogxK
U2 - 10.1097/RLU.0b013e31818f4369
DO - 10.1097/RLU.0b013e31818f4369
M3 - Article
C2 - 19092373
AN - SCOPUS:59649096113
VL - 34
SP - 7
EP - 10
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
SN - 0363-9762
IS - 1
ER -